Market Intelligence, Clinical Progress, and High-Purity Reagents for Leukemia, Vascular Disorders, and Diagnostic Pathology.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MYH11 / SMMHC drug discovery and diagnostic assay development. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MYH11 Recombinant Protein (Motor Domain / Rod Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for ATPase and binding assays. |
View MYH11 Products |
| Gene Delivery | MYH11 / CBFB-MYH11 Promise-ORF / Lentivirus Full-length ORF and fusion constructs for stable cell line generation and signaling validation. |
View MYH11 Products |
| Benchmark Ab | Anti-MYH11 Recombinant Antibody (SMMS-1 Sequence) Recombinant positive control for immunohistochemistry (IHC) and flow cytometry. |
View MYH11 Products |
| Validator | MYH11 siRNA Set Target-specific knockdown verification in smooth muscle and leukemia cell models. |
View MYH11 Products |
| Related Target A | CBFB Core binding factor subunit beta. Partners with MYH11 in inv(16) acute myeloid leukemia (AML). |
View CBFB Products |
| Related Target B | RUNX1 Runt-related transcription factor 1. Key component of the core binding factor complex disrupted by CBFB-MYH11. |
View RUNX1 Products |
| Related Target C | MYH9 Non-muscle myosin heavy chain IIA. Critical paralog for selectivity and off-target safety screening. |
View MYH9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Selectivity (MYH11 vs. MYH9/MYH7) | High-purity recombinant motor domains with sequence verification via mass spectrometry to ensure target-specific screening. |
| Insoluble High Molecular Weight Expression | Domain-specific truncations (active motor domain) optimized for soluble expression and high yield. |
| Lack of Controls | Sequence-defined recombinant benchmark antibodies (SMMS-1 biosimilar) for assay calibration. |
| Off-Target Phenotypes | Sequence-verified siRNA sets included for functional target knockdown validation. |
Live MYH11 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic and diagnostic targeting of MYH11 (Smooth Muscle Myosin Heavy Chain, SMMHC) spans oncology, cardiology, and pathology. In acute myeloid leukemia (AML), the inv(16)(p13q22) chromosomal inversion generates the oncogenic CBFB-MYH11 fusion protein, a validated driver of leukemogenesis. Current clinical development focuses on small-molecule protein-protein interaction (PPI) inhibitors designed to disrupt the CBFB-MYH11 complex, restoring normal RUNX1/CBFB transcriptional activity.
In vascular medicine, MYH11 mutations are linked to thoracic aortic aneurysms and dissections (TAAD). Research is directed toward modulating myosin motor activity and smooth muscle cell (SMC) phenotypic switching. Concurrently, MYH11 remains a gold-standard diagnostic immunohistochemical marker for distinguishing benign smooth muscle tumors from leiomyosarcomas, and evaluating myoepithelial integrity in breast cancer lesions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Consortia, Biotech Startups | inv(16) Acute Myeloid Leukemia (AML) | CBFB-MYH11 protein interaction assays (Requires high-purity CBFB and MYH11 fragments) |
| Allosteric Myosin Modulators | Cardiovascular Therapeutics Developers | Thoracic Aortic Aneurysm (TAAD) | ATPase activity kinetic assays (Requires functional MYH11 motor domain) |
| Diagnostic Antibodies | Pathology Reference Labs, IVD Manufacturers | Leiomyosarcoma, Breast DCIS | High-affinity, sequence-verified SMMHC antigen for IHC calibration |